Skip To Main Content
M. Lebbar on Muck Rack

M. Lebbar

As seen in: Canadian Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with M.

Contact M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

OVERWEIGHT AND OBESITY IN PEOPLE LIVING WITH TYPE 1 DIABETES: A CROSS-SECTIONAL ANALYSIS OF THE BETTER REGISTRY

|
By A. Bonhoure, M. Lalanne-Mistrih, V. Boudreau, V. Messier, M. Lebbar, M. Talbo, V. CALDERÓN, C. Grou, A. Brazeau, B. Tressieres, R. Rabasa-Lhoret
| Canadian Journal of Cardiology Verified
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Open in Who Shared View Duplicates (126) Issue with article?

A COMPARATIVE STUDY ON THE USE OF GLUCOSE-LOWERING AGENTS AS ADJUVANT THERAPY IN INDIVIDUALS WITH TYPE 1 DIABETES MELLITUS

|
By J. Liu, M. Lebbar, A. Bonhoure, C. Leroux
| Canadian Journal of Cardiology Verified
BACKGROUND Attaining optimal glucose control is a challenge for many people with type 1 diabetes (PwT1D). Adjuvant glucose-lowering drugs, such as metformin, glucagon-like peptide-1 receptor agonists (GLP1-RA), and sodium glucose co-transporter 2 inhibitors (iSGLT2), although mostly off-label, are used by PwT1D to improve health outcomes. We compared socio-demographic and disease-related characteristics of PwT1D using these drugs and of non-users.
Open in Who Shared Issue with article?
See all 2 articles